Disclosure Statement of Financial Interest

Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below.

Affiliation/Financial Relationship

Consulting Fees/Honoraria

- Royalty Income
- Ownership/Founder/Salary

Company

- Abbott Ventures, Inc.
- Ardelyx, Inc.
- Boston Scientific, Inc.
- Medtronic Vascular, Inc.
- Rainbow Medical, Inc.
- Nephera, Inc.
- Ardian, Inc.
- Cibiem, Inc.
- Rox Medical, Inc.

Two Approaches to Hypertension

• Modify....

- Regulation of the circulatory system

- Physical properties of the circulatory system

Mechanical Means of Reducing BP Create a Central (Iliac) Arterio-Venous Anastomosis

- Alter Cardiac output
 - Modify the efficiency of the heart
 - Reduce venous volume, and effective arterial volume
- Add Compliance into a Rigid Arterial Tree
- Reduce dynamic Vascular Resistance

Korsheed et al

Nephrol Dial Transplant (2011) 26: 3296–3302 doi: 10.1093/ndt/gfq851 Advance Access publication 11 February 2011

Original Articles




Effects of arteriovenous fistula formation on arterial stiffness and cardiovascular performance and function

Shvan Korsheed¹, Mohamed. T. Eldehni¹, Stephen G. John¹, Richard J. Fluck¹ and Christopher W. McIntyre^{1,2}


Conclusions. AVF formation resulted in a sustained reduction in arterial stiffness and BP as well as an increase in LVEF. Overall, post-AVF adaptations might be characterized as potentially beneficial in these patients and supports the widespread use of native vascular access, including older or cardiovascular compromised individuals.

Central AV Anastomosis for the treatment of Hypertension Proposed Mechanisms




A. Burchell, M.Lobo, P. Sobotka, J. Paton. In Press

The ROX Coupler Central A-V Anastomosis



ROX Coupler

- Fixed Size A-V Anastomosis
- No Change in Size or Flow over time



Immediately effective, Reversible Interventional Treatment for HTN A unique solution for ISH?

Post - FLOW Procedure

Placement of coupler between Artery & Vein

Femoral Arterial 4Fr & Venous 11Fr Access

Create anastomosis between the iliac artery and iliac vein


Lowers peripheral vascular resistance and restores compliance into the vascular system

Under 1 hour procedure in standard cath lab

No sedation required

Procedure is **fully reversible** – retain all other treatment options


Immediate Reduction of BP



No SHAM effect No Hawthorne effect No Placebo effect No Migration to Mean

Central AV Anastomosis to Treat HTN

- Impact on BP is
 Immediate
 - No sham/placebo effect
 - Patient/Clinician
 Satisfaction
- Only therapy addressing Compliance
- Treatment is Reversible
- Standard Cath
 Techniques Required



ROX Coupler HTN Experience


Initial trials in COPD

 Target to reduce pulmonary vascular resistance and improve the patient experience with end stage lung disease

 Revealed a predictable reduction in BP in patients with hypertension and no effect in normotensive patients

LVH Regression and Improved Diastolic Function

- Independently verified by two echo cardiologists
- Significant improvement in cardiac function post ROX procedure (n=5)



Sofie Brouwers, et al. ESC 2012

Potential Issues

- Effects of chronically elevating Cardiac Output by <1I/m
 - High output failure only reported >3l/m
 If PCWP rises, stent may be covered
- Turbulence and late venous stenosis
 - Clinically apparent with edema and loss of bp effect
 - Treatment: venous stent

URGENCY TO TREAT- REDUCE NOW!





Probability of stroke: a risk profile from the Framingham Study.


P A Wolf, R B D'Agostino, A J Belanger and W B Kannel

Stroke. 1991;22:312-318 doi: 10.1161/01.STR.22.3.312 Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231 Copyright © 1991 American Heart Association, Inc. All rights reserved. Print ISSN: 0039-2499. Online ISSN: 1524-4628

This model allows estimation of absolute risk of stroke at 1 year based on severity of hypertension


Example Patient A – Base Case with LVH

Absolute Risk of Stroke in 1 year (men)




Example Patient B – Add CVD

Absolute Risk of Stroke in 1 year (men)




Example Patient C – Add DM

Absolute Risk of Stroke in 1 year (men)




Example Patient D – Add Cigarettes

Absolute Risk of Stroke in 1 year (men)



Example Patient E – Add AF

Absolute Risk of Stroke in 1 year (men)



There's No Time to Waste!

- Treat to target is the goal of antihypertensive therapy
- Delay in reaching target blood pressure causes measurable risk of cardiovascular events, especially stroke
- Effective and prompt treatment of HTN can reduce CV risk and end organ disease

Rox Central AV Anastomosis

- Randomized, open label Clinical Trial in rHTN anticipated completion 1Q2014 – NCT01642498
 - Primary endpoints: 6 mo. ABPM (blinded endpoint) and oBP (open) endpoint trial
- Clinical Trial in additional disease spaces are being structured

Terminal Thoughts

